While medicine has traditionally aimed to be personalized, it has rarely been precise.
In the ever-evolving landscape of healthcare, Circular Genomics, a private company that just closed a $8.3MM Series A round earlier this year, stands out as a trailblazer in the pursuit of precision medicine in psychiatry. Co-founded by Dr. Nikoloas Mellios, a neuroscientist and former physician, the company is leveraging innovative biomarkers to transform the diagnosis and treatment of psychiatric disorders.
Comments